Valeant’s Bausch + Lomb Revenues Dip 3 percent in Q2-2017

August 11, 2017: By Jon Swedien

Valeant PharmaceuticalsValeant’s Pharmaceuticals’ Bausch + Lomb segment posted revenues of $1.24 billion in Q2-2017, a decrease of 3 percent (+1 percent, cc) compared with $1.28 billion for Q2-2016, the company reported Aug. 8.

In an earnings call, Valeant Chairman and CEO Joseph Papa said the Bausch + Lomb/International segment represented 56 percent of Valeant’s revenues in the quarter. He noted B+L’s strong performance in China (+4 percent, +9 percent cc), driven by volume.

Valeant posted total revenues of $2.23 billion in Q2-2017, an 8 percent decrease (-5 percent, cc) compared with Q2-2016.

The company said it remained committed to lowering its debt and had reduced the total by more than $4.8 billion since Q1-2016.

Its total long-term debt is currently $28.5 billion.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022